PharmaMar presents new data on Yondelis® (trabectedin) in combination with immunotherapy at ESMO
(World News Austria)

PharmaMar presents new data on Yondelis® (trabectedin) in combination with immunotherapy at ESMO New data on Yondelis® (trabectedin) in combination with immunotherapy (durvalumab) in pre-treated advanced Soft-Tissue Sarcoma patients has been presented during the Congress. The results show that trabectedin, in combination with durvalumab has a favourable activity, safety and efficacy profile in patients with pre-treated advanced Soft-Tissue Sarcoma. Madrid, September 21st, 2020.- At the European Society of Medical Oncology (ESMO) congress, the French Sarcoma Group, in collaboration with PharmaMar (MSE:PHM), presented in an oral session the latest results of Yondelis® (trabectedin), in...